pd 1  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc pd 1
    a , b Joint embedding showing the detailed annotation of the myeloid subpopulations ( a ) and the expression of select gene markers for each subpopulation ( b ). c Gene expression pattern: boxplots representing the average gene expression pattern of monocyte, macrophage, inflammatory, antigen processing and presentation, MDSC gene signatures, and M2-macrophages gene signature across the different myeloid subpopulations (top). Heatmap showing the average gene expression of representative genes across the different myeloid subpopulations in healthy, adj-normal, and tumor prostate samples (bottom). See Supplementary Data for the genes defining the above-mentioned signatures. d Boxplot comparing the average expression of MDSC gene signature in tumor-inflammatory monocytes (TIMo) across the three different samples (healthy n = 5, adj-normal n = 14, and tumor n = 18). e Boxplot representing the cell fraction of different myeloid subpopulations across the healthy ( n = 5), tumor ( n = 18), and their adj-normal ( n = 14) prostate tissues. Boxplots in c – e include centerline, median; box limits, upper and lower quartiles; and whiskers are highest and lowest values no >1.5× interquartile range. Statistical significance was accessed using two-sided Wilcoxon rank-sum test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001), p values could be found in Supplementary Data . f Top: multiplex fluorescence immunohistochemistry (mFIHC) staining of prostate tumor tissue (bottom) and its adj-normal tissue (top) collected from a prostatectomy case of Gleason score 5 + 5. Samples are labeled with PD-1 (Clone <t>EH33)</t> (color Red), FOXP3 (color Orange), CD8 (color Yellow), CD68 (color Magenta), CD3 (color Cyan), CD163 (color Green), and DAPI (Blue) by using mFIHC. Bottom: quantification of absolute number of macrophages (left) and M2-macrophages (right) from mIHC data comparing tumor tissues to their matched adj-normal tissues collected from prostatectomy cases of different Gleason scores. Red circles represent the tumor samples and black circles represent their matched adj-normal samples. Source data are provided as a Source Data file.
    Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd 1 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses"

    Article Title: Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses

    Journal: Nature Communications

    doi: 10.1038/s41467-023-36325-2

    a , b Joint embedding showing the detailed annotation of the myeloid subpopulations ( a ) and the expression of select gene markers for each subpopulation ( b ). c Gene expression pattern: boxplots representing the average gene expression pattern of monocyte, macrophage, inflammatory, antigen processing and presentation, MDSC gene signatures, and M2-macrophages gene signature across the different myeloid subpopulations (top). Heatmap showing the average gene expression of representative genes across the different myeloid subpopulations in healthy, adj-normal, and tumor prostate samples (bottom). See Supplementary Data for the genes defining the above-mentioned signatures. d Boxplot comparing the average expression of MDSC gene signature in tumor-inflammatory monocytes (TIMo) across the three different samples (healthy n = 5, adj-normal n = 14, and tumor n = 18). e Boxplot representing the cell fraction of different myeloid subpopulations across the healthy ( n = 5), tumor ( n = 18), and their adj-normal ( n = 14) prostate tissues. Boxplots in c – e include centerline, median; box limits, upper and lower quartiles; and whiskers are highest and lowest values no >1.5× interquartile range. Statistical significance was accessed using two-sided Wilcoxon rank-sum test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001), p values could be found in Supplementary Data . f Top: multiplex fluorescence immunohistochemistry (mFIHC) staining of prostate tumor tissue (bottom) and its adj-normal tissue (top) collected from a prostatectomy case of Gleason score 5 + 5. Samples are labeled with PD-1 (Clone EH33) (color Red), FOXP3 (color Orange), CD8 (color Yellow), CD68 (color Magenta), CD3 (color Cyan), CD163 (color Green), and DAPI (Blue) by using mFIHC. Bottom: quantification of absolute number of macrophages (left) and M2-macrophages (right) from mIHC data comparing tumor tissues to their matched adj-normal tissues collected from prostatectomy cases of different Gleason scores. Red circles represent the tumor samples and black circles represent their matched adj-normal samples. Source data are provided as a Source Data file.
    Figure Legend Snippet: a , b Joint embedding showing the detailed annotation of the myeloid subpopulations ( a ) and the expression of select gene markers for each subpopulation ( b ). c Gene expression pattern: boxplots representing the average gene expression pattern of monocyte, macrophage, inflammatory, antigen processing and presentation, MDSC gene signatures, and M2-macrophages gene signature across the different myeloid subpopulations (top). Heatmap showing the average gene expression of representative genes across the different myeloid subpopulations in healthy, adj-normal, and tumor prostate samples (bottom). See Supplementary Data for the genes defining the above-mentioned signatures. d Boxplot comparing the average expression of MDSC gene signature in tumor-inflammatory monocytes (TIMo) across the three different samples (healthy n = 5, adj-normal n = 14, and tumor n = 18). e Boxplot representing the cell fraction of different myeloid subpopulations across the healthy ( n = 5), tumor ( n = 18), and their adj-normal ( n = 14) prostate tissues. Boxplots in c – e include centerline, median; box limits, upper and lower quartiles; and whiskers are highest and lowest values no >1.5× interquartile range. Statistical significance was accessed using two-sided Wilcoxon rank-sum test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001), p values could be found in Supplementary Data . f Top: multiplex fluorescence immunohistochemistry (mFIHC) staining of prostate tumor tissue (bottom) and its adj-normal tissue (top) collected from a prostatectomy case of Gleason score 5 + 5. Samples are labeled with PD-1 (Clone EH33) (color Red), FOXP3 (color Orange), CD8 (color Yellow), CD68 (color Magenta), CD3 (color Cyan), CD163 (color Green), and DAPI (Blue) by using mFIHC. Bottom: quantification of absolute number of macrophages (left) and M2-macrophages (right) from mIHC data comparing tumor tissues to their matched adj-normal tissues collected from prostatectomy cases of different Gleason scores. Red circles represent the tumor samples and black circles represent their matched adj-normal samples. Source data are provided as a Source Data file.

    Techniques Used: Expressing, Multiplex Assay, Fluorescence, Immunohistochemistry, Staining, Labeling

    pd1  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc pd1
    Spatial distribution and correlations of characteristic immune cell markers in lymph nodes. The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells <t>(CD3+/CD8A-/PD1+)</t> is shown in the histogram. ∗∗ p < 0.01.
    Pd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd1 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "Immune Characters and Plasticity of the Sentinel Lymph Node in Colorectal Cancer Patients"

    Article Title: Immune Characters and Plasticity of the Sentinel Lymph Node in Colorectal Cancer Patients

    Journal: Journal of Immunology Research

    doi: 10.1155/2021/5516399

    Spatial distribution and correlations of characteristic immune cell markers in lymph nodes. The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) is shown in the histogram. ∗∗ p < 0.01.
    Figure Legend Snippet: Spatial distribution and correlations of characteristic immune cell markers in lymph nodes. The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) is shown in the histogram. ∗∗ p < 0.01.

    Techniques Used: Expressing

    The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) in SN and NSN of patients at different clinical stages.
    Figure Legend Snippet: The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) in SN and NSN of patients at different clinical stages.

    Techniques Used: Expressing

    mouse pd 1 antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc mouse pd 1 antibody
    Multiplex immunofluorescence in HLRCC type. A. DAPI nuclear stain. B. PD-L1 positive in green color. <t>C.</t> <t>PD-1</t> positive in magenta. D. CD8 + in white. E. Combination of markers without unmixing colors; note positive staining of PD-L1 at the tumor area (green) and peritumoral distribution of cells co-expressing CD8 + and PD1 + (pink color: magenta and white overlapped).
    Mouse Pd 1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse pd 1 antibody/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse pd 1 antibody - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma"

    Article Title: Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma

    Journal: Journal of Cancer

    doi: 10.7150/jca.35738

    Multiplex immunofluorescence in HLRCC type. A. DAPI nuclear stain. B. PD-L1 positive in green color. C. PD-1 positive in magenta. D. CD8 + in white. E. Combination of markers without unmixing colors; note positive staining of PD-L1 at the tumor area (green) and peritumoral distribution of cells co-expressing CD8 + and PD1 + (pink color: magenta and white overlapped).
    Figure Legend Snippet: Multiplex immunofluorescence in HLRCC type. A. DAPI nuclear stain. B. PD-L1 positive in green color. C. PD-1 positive in magenta. D. CD8 + in white. E. Combination of markers without unmixing colors; note positive staining of PD-L1 at the tumor area (green) and peritumoral distribution of cells co-expressing CD8 + and PD1 + (pink color: magenta and white overlapped).

    Techniques Used: Multiplex Assay, Immunofluorescence, Staining, Expressing

    eh33  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc eh33
    Eh33, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eh33/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    eh33 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    human pd 1  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc human pd 1
    (A) Immunohistochemical expression <t>of</t> <t>PD-1</t> and (B) immunohistochemical expression of PD-L1.
    Human Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human pd 1 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma"

    Article Title: Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma

    Journal: Frontiers in Endocrinology

    doi: 10.3389/fendo.2022.931647

    (A) Immunohistochemical expression of PD-1 and (B) immunohistochemical expression of PD-L1.
    Figure Legend Snippet: (A) Immunohistochemical expression of PD-1 and (B) immunohistochemical expression of PD-L1.

    Techniques Used: Immunohistochemical staining, Expressing

    (A) Relative mRNA expression of PD-1 and (B, C) relative mRNA expression of PD-L1.
    Figure Legend Snippet: (A) Relative mRNA expression of PD-1 and (B, C) relative mRNA expression of PD-L1.

    Techniques Used: Expressing

    anti pd 1  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc anti pd 1
    Anti Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pd 1 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    pd 1  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc pd 1
    <t>PD-1</t> + immune cell and T cell infiltration in AGCs. (a) Representative samples of IHC staining <t>of</t> <t>PD-1,</t> CD3, CD8, and FOXP3, including high and low infiltration for each marker, are presented. (b) The percent of tumor PD-L1-positive specimens in the high and low expression groups of PD-1, CD3, CD8, and FOXP3. ∗∗ P < 0.01; ns: no statistical significance.
    Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd 1 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "PD-L1 Expression and CD8 + T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer"

    Article Title: PD-L1 Expression and CD8 + T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer

    Journal: Journal of Immunology Research

    doi: 10.1155/2018/4180517

    PD-1 + immune cell and T cell infiltration in AGCs. (a) Representative samples of IHC staining of PD-1, CD3, CD8, and FOXP3, including high and low infiltration for each marker, are presented. (b) The percent of tumor PD-L1-positive specimens in the high and low expression groups of PD-1, CD3, CD8, and FOXP3. ∗∗ P < 0.01; ns: no statistical significance.
    Figure Legend Snippet: PD-1 + immune cell and T cell infiltration in AGCs. (a) Representative samples of IHC staining of PD-1, CD3, CD8, and FOXP3, including high and low infiltration for each marker, are presented. (b) The percent of tumor PD-L1-positive specimens in the high and low expression groups of PD-1, CD3, CD8, and FOXP3. ∗∗ P < 0.01; ns: no statistical significance.

    Techniques Used: Immunohistochemistry, Marker, Expressing

    The relationship between PD-L1 expression and T cell infiltration in 509 AGC patients and TCGA database. (a) The heat map of PD-1, CD3, CD8, and FOXP3 high and low infiltration in tumors of PD-L1-positive and -negative AGC patients. (b) The correlation between PD-L1 and CD8A mRNA expression levels in GC patients in the TCGA database.
    Figure Legend Snippet: The relationship between PD-L1 expression and T cell infiltration in 509 AGC patients and TCGA database. (a) The heat map of PD-1, CD3, CD8, and FOXP3 high and low infiltration in tumors of PD-L1-positive and -negative AGC patients. (b) The correlation between PD-L1 and CD8A mRNA expression levels in GC patients in the TCGA database.

    Techniques Used: Expressing

    Prognostic value of tumor PD-L1 expression and T cell infiltration in AGC patients. (a) Kaplan-Meier survival curves for OS based on PD-L1, PD-1, CD3, CD8, and FOXP3 status. (b) After univariate analysis, we selected statistically significant risk factors, including PD-L1, FOXP3, CD8, and other clinicopathological parameters, for multivariable analysis.
    Figure Legend Snippet: Prognostic value of tumor PD-L1 expression and T cell infiltration in AGC patients. (a) Kaplan-Meier survival curves for OS based on PD-L1, PD-1, CD3, CD8, and FOXP3 status. (b) After univariate analysis, we selected statistically significant risk factors, including PD-L1, FOXP3, CD8, and other clinicopathological parameters, for multivariable analysis.

    Techniques Used: Expressing

    pd 1  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc pd 1
    PD-L1 expression in primary lung tumors and BrMs. (A) Representative images of BrMs with H&E staining, PD-L1 by immunohistochemistry (22C3), and immunofluorescence (QIF). In the fluorescence image, simultaneous staining shows DAPI (blue), cytokeratin (gray), and PD-L1 (green). (B) Linear correlation coefficient between the PD-L1 expression as measured by TPS and QIF. Non-parametric, Spearman correlation ( r ) shows a significant moderate strength correlation (p<0.001). (C) PD-L1 expression in tumor and stroma as measured by visual assessment (TPS) or QIF in the tumor (tQIF) or QIF in the stroma (sQIF). No significant differences were found in PD-L1 tumor or stromal expression between primary lung tumors or brain tissues ( p >0.05). Overall PD-L1 expression in the stroma was markedly lower than that in the tumor compartment as measured by either visual assessment ( p =0.023) or QIF ( p =0.018). Expression is displayed as ratios normalized to the average expression in the lung. AU, artificial units; BrM, brain metastasis; DAPI, diamidino-2-phenylindolens; ns, not significant; PD-L1, programmed death-ligand 1; QIF, quantitative immunofluorescence; sQIF, quantitative immunofluorescence in the stroma; tQIF, quantitative immunofluorescence in the tumor; TPS, tumor proportion scoring.
    Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd 1 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases"

    Article Title: Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases

    Journal: Journal for Immunotherapy of Cancer

    doi: 10.1136/jitc-2021-002684

    PD-L1 expression in primary lung tumors and BrMs. (A) Representative images of BrMs with H&E staining, PD-L1 by immunohistochemistry (22C3), and immunofluorescence (QIF). In the fluorescence image, simultaneous staining shows DAPI (blue), cytokeratin (gray), and PD-L1 (green). (B) Linear correlation coefficient between the PD-L1 expression as measured by TPS and QIF. Non-parametric, Spearman correlation ( r ) shows a significant moderate strength correlation (p<0.001). (C) PD-L1 expression in tumor and stroma as measured by visual assessment (TPS) or QIF in the tumor (tQIF) or QIF in the stroma (sQIF). No significant differences were found in PD-L1 tumor or stromal expression between primary lung tumors or brain tissues ( p >0.05). Overall PD-L1 expression in the stroma was markedly lower than that in the tumor compartment as measured by either visual assessment ( p =0.023) or QIF ( p =0.018). Expression is displayed as ratios normalized to the average expression in the lung. AU, artificial units; BrM, brain metastasis; DAPI, diamidino-2-phenylindolens; ns, not significant; PD-L1, programmed death-ligand 1; QIF, quantitative immunofluorescence; sQIF, quantitative immunofluorescence in the stroma; tQIF, quantitative immunofluorescence in the tumor; TPS, tumor proportion scoring.
    Figure Legend Snippet: PD-L1 expression in primary lung tumors and BrMs. (A) Representative images of BrMs with H&E staining, PD-L1 by immunohistochemistry (22C3), and immunofluorescence (QIF). In the fluorescence image, simultaneous staining shows DAPI (blue), cytokeratin (gray), and PD-L1 (green). (B) Linear correlation coefficient between the PD-L1 expression as measured by TPS and QIF. Non-parametric, Spearman correlation ( r ) shows a significant moderate strength correlation (p<0.001). (C) PD-L1 expression in tumor and stroma as measured by visual assessment (TPS) or QIF in the tumor (tQIF) or QIF in the stroma (sQIF). No significant differences were found in PD-L1 tumor or stromal expression between primary lung tumors or brain tissues ( p >0.05). Overall PD-L1 expression in the stroma was markedly lower than that in the tumor compartment as measured by either visual assessment ( p =0.023) or QIF ( p =0.018). Expression is displayed as ratios normalized to the average expression in the lung. AU, artificial units; BrM, brain metastasis; DAPI, diamidino-2-phenylindolens; ns, not significant; PD-L1, programmed death-ligand 1; QIF, quantitative immunofluorescence; sQIF, quantitative immunofluorescence in the stroma; tQIF, quantitative immunofluorescence in the tumor; TPS, tumor proportion scoring.

    Techniques Used: Expressing, Staining, Immunohistochemistry, Immunofluorescence, Fluorescence

    CD3 + T cell expression of the coinhibitory receptors in primary lung tumors and BrMs. (A) Representative fluorescence images showing the simultaneous staining of DAPI (blue), CD3 (red), PD-1 (yellow), TIM-3 (purple), and LAG-3 (green) in primary lung tumors and BrMs. (B) CD3+ T cells within BrMs have lower expression of PD-1 ( p =0.013), Tim-3 ( p =0.021), and LAG-3 ( p =0.008) compared with primary lung tumors, as measured by QIF. Expression is displayed as ratios normalized to the average expression in the lung. (C) High TIM-3 ( p =0.041) and LAG-3 ( p =0.035) expression in CD3+ T cells in BrMs were associated with longer survival. The median cutpoint was used to define high/low expression. BrM, brain metastasis; LAG-3, lymphocyte activation gene 3; PD-1, programmed cell death 1; QIF, quantitative immunofluorescence; TIM-3, T cell immunoglobulin mucin receptor 3. Asterix (*) indicates p <0.05.
    Figure Legend Snippet: CD3 + T cell expression of the coinhibitory receptors in primary lung tumors and BrMs. (A) Representative fluorescence images showing the simultaneous staining of DAPI (blue), CD3 (red), PD-1 (yellow), TIM-3 (purple), and LAG-3 (green) in primary lung tumors and BrMs. (B) CD3+ T cells within BrMs have lower expression of PD-1 ( p =0.013), Tim-3 ( p =0.021), and LAG-3 ( p =0.008) compared with primary lung tumors, as measured by QIF. Expression is displayed as ratios normalized to the average expression in the lung. (C) High TIM-3 ( p =0.041) and LAG-3 ( p =0.035) expression in CD3+ T cells in BrMs were associated with longer survival. The median cutpoint was used to define high/low expression. BrM, brain metastasis; LAG-3, lymphocyte activation gene 3; PD-1, programmed cell death 1; QIF, quantitative immunofluorescence; TIM-3, T cell immunoglobulin mucin receptor 3. Asterix (*) indicates p <0.05.

    Techniques Used: Expressing, Fluorescence, Staining, Activation Assay, Immunofluorescence

    anti pd 1 antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc anti pd 1 antibody
    Differences in tertiary lymphoid structure (TLS) status between kidney and bladder cancer. (A) Differences in TLS maturity between clear cell renal cell carcinoma (ccRCC) (cohort A) and bladder cancer (cohort D). The p value was obtained from the chi-square test. (B) Differences in TLS distribution between ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (C) Comparison of the tumor area occupied by the TLSs in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the Mann-Whitney U test. (D) Differences in TLS status according to the infiltration of CD8 + /FOXP3 <t>+</t> <t>/PD-1</t> + /PD-L1 + cells in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (E) summary of TLS status in all tumors of the ccRCC cohort (cohort a) and bladder cancer cohort (cohort D).
    Anti Pd 1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pd 1 antibody/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pd 1 antibody - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer"

    Article Title: Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer

    Journal: Journal for Immunotherapy of Cancer

    doi: 10.1136/jitc-2021-003883

    Differences in tertiary lymphoid structure (TLS) status between kidney and bladder cancer. (A) Differences in TLS maturity between clear cell renal cell carcinoma (ccRCC) (cohort A) and bladder cancer (cohort D). The p value was obtained from the chi-square test. (B) Differences in TLS distribution between ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (C) Comparison of the tumor area occupied by the TLSs in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the Mann-Whitney U test. (D) Differences in TLS status according to the infiltration of CD8 + /FOXP3 + /PD-1 + /PD-L1 + cells in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (E) summary of TLS status in all tumors of the ccRCC cohort (cohort a) and bladder cancer cohort (cohort D).
    Figure Legend Snippet: Differences in tertiary lymphoid structure (TLS) status between kidney and bladder cancer. (A) Differences in TLS maturity between clear cell renal cell carcinoma (ccRCC) (cohort A) and bladder cancer (cohort D). The p value was obtained from the chi-square test. (B) Differences in TLS distribution between ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (C) Comparison of the tumor area occupied by the TLSs in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the Mann-Whitney U test. (D) Differences in TLS status according to the infiltration of CD8 + /FOXP3 + /PD-1 + /PD-L1 + cells in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (E) summary of TLS status in all tumors of the ccRCC cohort (cohort a) and bladder cancer cohort (cohort D).

    Techniques Used: MANN-WHITNEY

    anti pd 1  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cell Signaling Technology Inc anti pd 1
    Stromal CD8 + effector T cells are associated with better outcome after ICI in NSCLC cases with PD-L1 expressing tumors. (A) TILs density by compartment based on PD-L1 status. (B–E) Forest plots showing the PFS and OS Hazard ratios calculated for the continuous levels of each TIL marker using a Cox univariate model in PD-L1 positive (B and C) and negative cases (D and E). (F–I) Kaplan-Meier graphical analysis of the PFS and OS of cases in the cohort stratified by high (top 15% of scores) and low (bottom 85% of scores) density of stromal CD8 + T cells in the PD-L1 positive and negative group. ICI, immune checkpoint blockers; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival; TIL, tumor infiltrating lymphocyte.
    Anti Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pd 1 - by Bioz Stars, 2024-07
    95/100 stars

    Images

    1) Product Images from "Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer"

    Article Title: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

    Journal: Journal for Immunotherapy of Cancer

    doi: 10.1136/jitc-2021-004440

    Stromal CD8 + effector T cells are associated with better outcome after ICI in NSCLC cases with PD-L1 expressing tumors. (A) TILs density by compartment based on PD-L1 status. (B–E) Forest plots showing the PFS and OS Hazard ratios calculated for the continuous levels of each TIL marker using a Cox univariate model in PD-L1 positive (B and C) and negative cases (D and E). (F–I) Kaplan-Meier graphical analysis of the PFS and OS of cases in the cohort stratified by high (top 15% of scores) and low (bottom 85% of scores) density of stromal CD8 + T cells in the PD-L1 positive and negative group. ICI, immune checkpoint blockers; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival; TIL, tumor infiltrating lymphocyte.
    Figure Legend Snippet: Stromal CD8 + effector T cells are associated with better outcome after ICI in NSCLC cases with PD-L1 expressing tumors. (A) TILs density by compartment based on PD-L1 status. (B–E) Forest plots showing the PFS and OS Hazard ratios calculated for the continuous levels of each TIL marker using a Cox univariate model in PD-L1 positive (B and C) and negative cases (D and E). (F–I) Kaplan-Meier graphical analysis of the PFS and OS of cases in the cohort stratified by high (top 15% of scores) and low (bottom 85% of scores) density of stromal CD8 + T cells in the PD-L1 positive and negative group. ICI, immune checkpoint blockers; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival; TIL, tumor infiltrating lymphocyte.

    Techniques Used: Expressing, Marker

    The TCR fraction is associated with better outcome after ICI in PD-L1 positive NSCLC cases. (A) Overview of the TCR burden analysis protocol. (B) Forest plots showing the PFS and OS Hazard ratios of cases in the NSCLC cohort using a Cox univariate model. Cases were stratified by PD-L1 expression into positive (B) and negative (C) by immunohistochemistry. (D). Kaplan-Meier graphical analysis of PFS (D) and OS (E) of NSCLC cases stratified by the median TCR fraction and by PD-L1 status (F and G). ICI, Immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival; TCR, T cell receptor.
    Figure Legend Snippet: The TCR fraction is associated with better outcome after ICI in PD-L1 positive NSCLC cases. (A) Overview of the TCR burden analysis protocol. (B) Forest plots showing the PFS and OS Hazard ratios of cases in the NSCLC cohort using a Cox univariate model. Cases were stratified by PD-L1 expression into positive (B) and negative (C) by immunohistochemistry. (D). Kaplan-Meier graphical analysis of PFS (D) and OS (E) of NSCLC cases stratified by the median TCR fraction and by PD-L1 status (F and G). ICI, Immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death ligand-1; PFS, progression-free survival; TCR, T cell receptor.

    Techniques Used: Expressing, Immunohistochemistry

    Elevated T cell exhaustion/dysfuntion markers are associated with worse outcomes after ICI in NSCLC. (A) Representative multicolor immunofluorescence captions showing DAPI (dark blue), CD3 (cyan), LAG-3 (orange), PD-1 (red) and TIM-3 (green) staining in NSCLC cases. (B) Bar plot for the distribution of the normalized expression of exhaustion markers in the CD3 compartment across the cohort. (C–E) Correlation between expression of TIM-3 and LAG-3 (C), LAG-3 and PD-1 (D), PD-1 and TIM-3 (E). Results show Pearson’s r correlation coefficient. (F–K) Kaplan-Meier graphical analysis of the progression-free survival and overall survival for the normalized QIF scores for LAG-3, PD-1 and TIM-3 measured selectively in CD3 + T cells. DAPI, 4’,6-Diamidino-2-Phenylindole; NSCLC, non-small cell lung cancer; TIM-3, T cell immunoglobulin mucin-3; LAG-3, lymphocyte-activation gene 3 (LAG-3); PD-1, programmed cell death protein-1; QIF, quantitative immunofluorescence.
    Figure Legend Snippet: Elevated T cell exhaustion/dysfuntion markers are associated with worse outcomes after ICI in NSCLC. (A) Representative multicolor immunofluorescence captions showing DAPI (dark blue), CD3 (cyan), LAG-3 (orange), PD-1 (red) and TIM-3 (green) staining in NSCLC cases. (B) Bar plot for the distribution of the normalized expression of exhaustion markers in the CD3 compartment across the cohort. (C–E) Correlation between expression of TIM-3 and LAG-3 (C), LAG-3 and PD-1 (D), PD-1 and TIM-3 (E). Results show Pearson’s r correlation coefficient. (F–K) Kaplan-Meier graphical analysis of the progression-free survival and overall survival for the normalized QIF scores for LAG-3, PD-1 and TIM-3 measured selectively in CD3 + T cells. DAPI, 4’,6-Diamidino-2-Phenylindole; NSCLC, non-small cell lung cancer; TIM-3, T cell immunoglobulin mucin-3; LAG-3, lymphocyte-activation gene 3 (LAG-3); PD-1, programmed cell death protein-1; QIF, quantitative immunofluorescence.

    Techniques Used: Immunofluorescence, Staining, Expressing, Activation Assay

    High spatial immune heterogeneity is associated with worse survival after ICI in NSCLC. (A) Graphical representation of cases with low RQI (left) and high RQI (right) immune heterogeneity scores. (B) Violin plot showing the RQI in individual cell subsets obtained from NSCLCs in the cohort. (C) Bar Plot showing the distribution of the for the integrated RQI scores calculated from all cell subsets in the cohort cases. (D–E) Survival analysis of progression-free survival and overall survival of NSCLC cases stratified by the mean integrated RQI of the cohort. (F–G) Survival analysis of cases stratified by the mean integrated RQI based on the PD-L1 status. NSCLC, non-small lung cancer; PD-L1, programmed death ligand-1; RQI, Rao’s Q Index.
    Figure Legend Snippet: High spatial immune heterogeneity is associated with worse survival after ICI in NSCLC. (A) Graphical representation of cases with low RQI (left) and high RQI (right) immune heterogeneity scores. (B) Violin plot showing the RQI in individual cell subsets obtained from NSCLCs in the cohort. (C) Bar Plot showing the distribution of the for the integrated RQI scores calculated from all cell subsets in the cohort cases. (D–E) Survival analysis of progression-free survival and overall survival of NSCLC cases stratified by the mean integrated RQI of the cohort. (F–G) Survival analysis of cases stratified by the mean integrated RQI based on the PD-L1 status. NSCLC, non-small lung cancer; PD-L1, programmed death ligand-1; RQI, Rao’s Q Index.

    Techniques Used:

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Cell Signaling Technology Inc pd 1
    a , b Joint embedding showing the detailed annotation of the myeloid subpopulations ( a ) and the expression of select gene markers for each subpopulation ( b ). c Gene expression pattern: boxplots representing the average gene expression pattern of monocyte, macrophage, inflammatory, antigen processing and presentation, MDSC gene signatures, and M2-macrophages gene signature across the different myeloid subpopulations (top). Heatmap showing the average gene expression of representative genes across the different myeloid subpopulations in healthy, adj-normal, and tumor prostate samples (bottom). See Supplementary Data for the genes defining the above-mentioned signatures. d Boxplot comparing the average expression of MDSC gene signature in tumor-inflammatory monocytes (TIMo) across the three different samples (healthy n = 5, adj-normal n = 14, and tumor n = 18). e Boxplot representing the cell fraction of different myeloid subpopulations across the healthy ( n = 5), tumor ( n = 18), and their adj-normal ( n = 14) prostate tissues. Boxplots in c – e include centerline, median; box limits, upper and lower quartiles; and whiskers are highest and lowest values no >1.5× interquartile range. Statistical significance was accessed using two-sided Wilcoxon rank-sum test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001), p values could be found in Supplementary Data . f Top: multiplex fluorescence immunohistochemistry (mFIHC) staining of prostate tumor tissue (bottom) and its adj-normal tissue (top) collected from a prostatectomy case of Gleason score 5 + 5. Samples are labeled with PD-1 (Clone <t>EH33)</t> (color Red), FOXP3 (color Orange), CD8 (color Yellow), CD68 (color Magenta), CD3 (color Cyan), CD163 (color Green), and DAPI (Blue) by using mFIHC. Bottom: quantification of absolute number of macrophages (left) and M2-macrophages (right) from mIHC data comparing tumor tissues to their matched adj-normal tissues collected from prostatectomy cases of different Gleason scores. Red circles represent the tumor samples and black circles represent their matched adj-normal samples. Source data are provided as a Source Data file.
    Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd 1 - by Bioz Stars, 2024-07
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc pd1
    Spatial distribution and correlations of characteristic immune cell markers in lymph nodes. The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells <t>(CD3+/CD8A-/PD1+)</t> is shown in the histogram. ∗∗ p < 0.01.
    Pd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd1 - by Bioz Stars, 2024-07
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc mouse pd 1 antibody
    Multiplex immunofluorescence in HLRCC type. A. DAPI nuclear stain. B. PD-L1 positive in green color. <t>C.</t> <t>PD-1</t> positive in magenta. D. CD8 + in white. E. Combination of markers without unmixing colors; note positive staining of PD-L1 at the tumor area (green) and peritumoral distribution of cells co-expressing CD8 + and PD1 + (pink color: magenta and white overlapped).
    Mouse Pd 1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse pd 1 antibody/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse pd 1 antibody - by Bioz Stars, 2024-07
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc eh33
    Multiplex immunofluorescence in HLRCC type. A. DAPI nuclear stain. B. PD-L1 positive in green color. <t>C.</t> <t>PD-1</t> positive in magenta. D. CD8 + in white. E. Combination of markers without unmixing colors; note positive staining of PD-L1 at the tumor area (green) and peritumoral distribution of cells co-expressing CD8 + and PD1 + (pink color: magenta and white overlapped).
    Eh33, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/eh33/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    eh33 - by Bioz Stars, 2024-07
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc human pd 1
    (A) Immunohistochemical expression <t>of</t> <t>PD-1</t> and (B) immunohistochemical expression of PD-L1.
    Human Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human pd 1 - by Bioz Stars, 2024-07
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti pd 1
    (A) Immunohistochemical expression <t>of</t> <t>PD-1</t> and (B) immunohistochemical expression of PD-L1.
    Anti Pd 1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pd 1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pd 1 - by Bioz Stars, 2024-07
    95/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc anti pd 1 antibody
    Differences in tertiary lymphoid structure (TLS) status between kidney and bladder cancer. (A) Differences in TLS maturity between clear cell renal cell carcinoma (ccRCC) (cohort A) and bladder cancer (cohort D). The p value was obtained from the chi-square test. (B) Differences in TLS distribution between ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (C) Comparison of the tumor area occupied by the TLSs in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the Mann-Whitney U test. (D) Differences in TLS status according to the infiltration of CD8 + /FOXP3 <t>+</t> <t>/PD-1</t> + /PD-L1 + cells in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (E) summary of TLS status in all tumors of the ccRCC cohort (cohort a) and bladder cancer cohort (cohort D).
    Anti Pd 1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pd 1 antibody/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pd 1 antibody - by Bioz Stars, 2024-07
    95/100 stars
      Buy from Supplier

    Image Search Results


    a , b Joint embedding showing the detailed annotation of the myeloid subpopulations ( a ) and the expression of select gene markers for each subpopulation ( b ). c Gene expression pattern: boxplots representing the average gene expression pattern of monocyte, macrophage, inflammatory, antigen processing and presentation, MDSC gene signatures, and M2-macrophages gene signature across the different myeloid subpopulations (top). Heatmap showing the average gene expression of representative genes across the different myeloid subpopulations in healthy, adj-normal, and tumor prostate samples (bottom). See Supplementary Data for the genes defining the above-mentioned signatures. d Boxplot comparing the average expression of MDSC gene signature in tumor-inflammatory monocytes (TIMo) across the three different samples (healthy n = 5, adj-normal n = 14, and tumor n = 18). e Boxplot representing the cell fraction of different myeloid subpopulations across the healthy ( n = 5), tumor ( n = 18), and their adj-normal ( n = 14) prostate tissues. Boxplots in c – e include centerline, median; box limits, upper and lower quartiles; and whiskers are highest and lowest values no >1.5× interquartile range. Statistical significance was accessed using two-sided Wilcoxon rank-sum test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001), p values could be found in Supplementary Data . f Top: multiplex fluorescence immunohistochemistry (mFIHC) staining of prostate tumor tissue (bottom) and its adj-normal tissue (top) collected from a prostatectomy case of Gleason score 5 + 5. Samples are labeled with PD-1 (Clone EH33) (color Red), FOXP3 (color Orange), CD8 (color Yellow), CD68 (color Magenta), CD3 (color Cyan), CD163 (color Green), and DAPI (Blue) by using mFIHC. Bottom: quantification of absolute number of macrophages (left) and M2-macrophages (right) from mIHC data comparing tumor tissues to their matched adj-normal tissues collected from prostatectomy cases of different Gleason scores. Red circles represent the tumor samples and black circles represent their matched adj-normal samples. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses

    doi: 10.1038/s41467-023-36325-2

    Figure Lengend Snippet: a , b Joint embedding showing the detailed annotation of the myeloid subpopulations ( a ) and the expression of select gene markers for each subpopulation ( b ). c Gene expression pattern: boxplots representing the average gene expression pattern of monocyte, macrophage, inflammatory, antigen processing and presentation, MDSC gene signatures, and M2-macrophages gene signature across the different myeloid subpopulations (top). Heatmap showing the average gene expression of representative genes across the different myeloid subpopulations in healthy, adj-normal, and tumor prostate samples (bottom). See Supplementary Data for the genes defining the above-mentioned signatures. d Boxplot comparing the average expression of MDSC gene signature in tumor-inflammatory monocytes (TIMo) across the three different samples (healthy n = 5, adj-normal n = 14, and tumor n = 18). e Boxplot representing the cell fraction of different myeloid subpopulations across the healthy ( n = 5), tumor ( n = 18), and their adj-normal ( n = 14) prostate tissues. Boxplots in c – e include centerline, median; box limits, upper and lower quartiles; and whiskers are highest and lowest values no >1.5× interquartile range. Statistical significance was accessed using two-sided Wilcoxon rank-sum test (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001), p values could be found in Supplementary Data . f Top: multiplex fluorescence immunohistochemistry (mFIHC) staining of prostate tumor tissue (bottom) and its adj-normal tissue (top) collected from a prostatectomy case of Gleason score 5 + 5. Samples are labeled with PD-1 (Clone EH33) (color Red), FOXP3 (color Orange), CD8 (color Yellow), CD68 (color Magenta), CD3 (color Cyan), CD163 (color Green), and DAPI (Blue) by using mFIHC. Bottom: quantification of absolute number of macrophages (left) and M2-macrophages (right) from mIHC data comparing tumor tissues to their matched adj-normal tissues collected from prostatectomy cases of different Gleason scores. Red circles represent the tumor samples and black circles represent their matched adj-normal samples. Source data are provided as a Source Data file.

    Article Snippet: A six antibodies panel consisted of CD3 (Rabbit polyclonal, Dako), CD8 (C8/144B, Mouse monoclonal, Dako), PD-1(EH33, Mouse monoclonal, Cell Signaling), FOXP3 (D2W8E, Rabbit monoclonal, Cell Signaling), CD68 (PG-M1, Mouse monoclonal, Dako), CD163 (10D6, Mouse monoclonal, Leica Biosystem), along with DAPI counterstaining.

    Techniques: Expressing, Multiplex Assay, Fluorescence, Immunohistochemistry, Staining, Labeling

    Spatial distribution and correlations of characteristic immune cell markers in lymph nodes. The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) is shown in the histogram. ∗∗ p < 0.01.

    Journal: Journal of Immunology Research

    Article Title: Immune Characters and Plasticity of the Sentinel Lymph Node in Colorectal Cancer Patients

    doi: 10.1155/2021/5516399

    Figure Lengend Snippet: Spatial distribution and correlations of characteristic immune cell markers in lymph nodes. The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) is shown in the histogram. ∗∗ p < 0.01.

    Article Snippet: Immune cell panels included the following antibodies: CD3 (1 : 200, Abcam, ab16669), CD8A (1 : 300, Cell Signaling Technology, 70306), Foxp3 (1 : 500, Abcam, 20034), PD1 (1 : 50, Cell Signaling Technology, 43248), and CD163 (1 : 100, Cell Signaling Technology, 93498).

    Techniques: Expressing

    The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) in SN and NSN of patients at different clinical stages.

    Journal: Journal of Immunology Research

    Article Title: Immune Characters and Plasticity of the Sentinel Lymph Node in Colorectal Cancer Patients

    doi: 10.1155/2021/5516399

    Figure Lengend Snippet: The expression of M2 macrophages (CD3-/CD163+), Tregs (CD3+/CD8A-/FoxP3+), and Tfh cells (CD3+/CD8A-/PD1+) in SN and NSN of patients at different clinical stages.

    Article Snippet: Immune cell panels included the following antibodies: CD3 (1 : 200, Abcam, ab16669), CD8A (1 : 300, Cell Signaling Technology, 70306), Foxp3 (1 : 500, Abcam, 20034), PD1 (1 : 50, Cell Signaling Technology, 43248), and CD163 (1 : 100, Cell Signaling Technology, 93498).

    Techniques: Expressing

    Multiplex immunofluorescence in HLRCC type. A. DAPI nuclear stain. B. PD-L1 positive in green color. C. PD-1 positive in magenta. D. CD8 + in white. E. Combination of markers without unmixing colors; note positive staining of PD-L1 at the tumor area (green) and peritumoral distribution of cells co-expressing CD8 + and PD1 + (pink color: magenta and white overlapped).

    Journal: Journal of Cancer

    Article Title: Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma

    doi: 10.7150/jca.35738

    Figure Lengend Snippet: Multiplex immunofluorescence in HLRCC type. A. DAPI nuclear stain. B. PD-L1 positive in green color. C. PD-1 positive in magenta. D. CD8 + in white. E. Combination of markers without unmixing colors; note positive staining of PD-L1 at the tumor area (green) and peritumoral distribution of cells co-expressing CD8 + and PD1 + (pink color: magenta and white overlapped).

    Article Snippet: For PD-1, we used a primary anti mouse PD-1 antibody, clone EH33 (Cell Signaling.

    Techniques: Multiplex Assay, Immunofluorescence, Staining, Expressing

    (A) Immunohistochemical expression of PD-1 and (B) immunohistochemical expression of PD-L1.

    Journal: Frontiers in Endocrinology

    Article Title: Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma

    doi: 10.3389/fendo.2022.931647

    Figure Lengend Snippet: (A) Immunohistochemical expression of PD-1 and (B) immunohistochemical expression of PD-L1.

    Article Snippet: The primary antibody to human PD-1 (clone EH33; mouse mAb, Cell Signaling Technology: Massachusetts, USA) and PD-L1 (clone E1L3N, rabbit mAb, Cell Signaling Technology: Massachusetts, USA) at room temperature was added and incubated for 45–60 min.

    Techniques: Immunohistochemical staining, Expressing

    (A) Relative mRNA expression of PD-1 and (B, C) relative mRNA expression of PD-L1.

    Journal: Frontiers in Endocrinology

    Article Title: Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma

    doi: 10.3389/fendo.2022.931647

    Figure Lengend Snippet: (A) Relative mRNA expression of PD-1 and (B, C) relative mRNA expression of PD-L1.

    Article Snippet: The primary antibody to human PD-1 (clone EH33; mouse mAb, Cell Signaling Technology: Massachusetts, USA) and PD-L1 (clone E1L3N, rabbit mAb, Cell Signaling Technology: Massachusetts, USA) at room temperature was added and incubated for 45–60 min.

    Techniques: Expressing

    Differences in tertiary lymphoid structure (TLS) status between kidney and bladder cancer. (A) Differences in TLS maturity between clear cell renal cell carcinoma (ccRCC) (cohort A) and bladder cancer (cohort D). The p value was obtained from the chi-square test. (B) Differences in TLS distribution between ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (C) Comparison of the tumor area occupied by the TLSs in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the Mann-Whitney U test. (D) Differences in TLS status according to the infiltration of CD8 + /FOXP3 + /PD-1 + /PD-L1 + cells in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (E) summary of TLS status in all tumors of the ccRCC cohort (cohort a) and bladder cancer cohort (cohort D).

    Journal: Journal for Immunotherapy of Cancer

    Article Title: Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer

    doi: 10.1136/jitc-2021-003883

    Figure Lengend Snippet: Differences in tertiary lymphoid structure (TLS) status between kidney and bladder cancer. (A) Differences in TLS maturity between clear cell renal cell carcinoma (ccRCC) (cohort A) and bladder cancer (cohort D). The p value was obtained from the chi-square test. (B) Differences in TLS distribution between ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (C) Comparison of the tumor area occupied by the TLSs in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the Mann-Whitney U test. (D) Differences in TLS status according to the infiltration of CD8 + /FOXP3 + /PD-1 + /PD-L1 + cells in ccRCC (cohort A) and bladder cancer (cohort D). The p value was obtained from the χ2 test. (E) summary of TLS status in all tumors of the ccRCC cohort (cohort a) and bladder cancer cohort (cohort D).

    Article Snippet: The primary antibodies used were as follows: anti-Bcl6 antibody (#418181, Nichirei., Tokyo, Japan), anti-CD3 antibody (#413591, Nichirei., Tokyo, Japan), anti-CD8 antibody (#413211, Nichirei., Tokyo, Japan), anti-CD10 antibody (#413261, Nichirei., Tokyo, Japan), anti-CD20 antibody (#422441, Nichirei., Tokyo, Japan), anti-CD21 antibody (#M0784, Dako), anti-FOXP3 antibody (to label Treg cells, #ab20034, Abcam), anti-PD-1 antibody (#43248, Cell Signaling Technology), and anti-PD-L1 antibody (#13684, Cell Signaling Technology).

    Techniques: MANN-WHITNEY